

Resignation of member of the Board of Directors

Milan, 1st August 2014 - MolMed S.p.A. (Milan: MLM) announces the resignation, communicated today to the Company and with immediate effect, of Maurizio Carfagna from the office of non-executive member of the Board of Directors, motivated by the increasing responsibilities within the Doris group, which would not allow him to devote the due time and commitment to the Company. Maurizio Carfagna does not hold any Company shares.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Marina Del Bue

General Manager Business & Administration

a.i. Director Investor Relations

MolMed S.p.A.

phone: +39 02 21277.371

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@segrp.it

DISCLAIMER

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325

info@molmed.com - www.molmed.com

Share capital € 10,874,215.42 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



PRESS RELEASE

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.